Form 4: Merck Director Mary Ellen Coe Acquires Phantom Stock
Insider Transaction Report
Merck & Co. Director Mary Ellen Coe acquired 357.4407 phantom stock units, valued at $83.93 per unit, increasing her beneficial ownership to 28,684.663 units.
Summary
- Mary Ellen Coe, a Director at Merck & Co., Inc. [MRK], acquired derivative securities in the form of phantom stock units.
- On September 30, 2025, she acquired 357.4407 phantom stock units.
- Each phantom stock unit was valued at $83.93.
- These phantom stock units are equivalent to common stock and are designated to be settled 100% in cash upon her termination of service, in accordance with a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation.
- Following this transaction, her total beneficial ownership of derivative securities (phantom stock) is 28,684.663 units.
- Her reported holdings also include shares acquired through dividend reinvestment transactions.
Sentiment
Score: 7
Explanation: The acquisition of phantom stock by a director, particularly as part of a deferred compensation plan, generally indicates continued alignment of interests with the company's long-term performance and is a positive signal for investor confidence, though it is a routine compensation event.
Positives
- Director Coe increased her beneficial ownership in the company through the acquisition of phantom stock units, which aligns her interests with shareholders' long-term value creation.
- The phantom stock units are part of a structured deferred compensation plan, indicating a clear and established approach to executive incentives and retention.
Future Outlook
The phantom stock units are structured to be settled 100% in cash upon the reporting person's termination of service, in accordance with a pre-elected distribution schedule under the company's deferred payment plan for directors.
Industry Context
This filing represents a routine insider transaction, specifically the acquisition of derivative securities as part of a director's compensation package. Such transactions are common across publicly traded companies as a mechanism for aligning management and director interests with long-term shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Detail | Phantom stock units are to be settled 100% in cash upon the reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. | 09/30/2025 | Reinforces long-term alignment of the director's interests with company performance and provides a structured deferred compensation mechanism, contributing to stable corporate governance. |
Stakeholder Impact
- Shareholders: The transaction indicates continued alignment of Director Coe's interests with long-term shareholder value through her participation in the company's phantom stock plan.
Next Steps
- Settlement of the phantom stock units in cash upon Mary Ellen Coe's termination of service, as per the elected distribution schedule.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of earliest transaction, specifically the acquisition of phantom stock units. |
| 10/02/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Recommendation
holdThis Form 4 filing reports a routine acquisition of phantom stock units by a director as part of a deferred compensation plan. While it indicates continued alignment of management interests, it does not present new information that would fundamentally alter the investment thesis for Merck & Co., Inc. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.
Keywords
Merck & Co., MRK, Mary Ellen Coe, Director, Phantom Stock, Insider Transaction, SEC Form 4, Beneficial Ownership, Deferred Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.